The effect of Ginger powder consumption on some genes expression that are mediators of immunity and inflammation in adult with Rheumatoid Arthritis

The effect of Ginger supplementation consumption on some genes expression that are mediators of immunity and inflammation in adult with active Rheumatoid Arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201403109472N6

Enrollment

Registered

2014-03-19

Start date

2014-03-11

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adult active Rheumatoid arthritis. Rheumatoid arthritis, unspecified

Interventions

Intervention 1: Intervention Group: Patients that refer to hospital shariatti have interval criteria and will receive Ginger voluntarily. Patients in case group will receive 1500 mg of powdered Ginger

Treatment - Drugs

Placebo

Intervention Group: Patients that refer to hospital shariatti have interval criteria and will receive Ginger voluntarily. Patients in case group will receive 1500 mg of powdered Ginger daily (by two 7

Control groups: Patients that refer to hospital shariatti have interval criteria and will receive starch or flour voluntarily. Patients in Control group will receive 1500 mg of wheat flour daily (by t

Eligibility

Sex/Gender

All

Age

18 Years to 69 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: person with RA diseases as ACR criteria, having RA from 2 years ago; age between 18-69 years; not being pregnant or lactated; not smoking and drink alcohol; haven’t eaten multivitamin or antioxidants supplements from 3 month ago; don't eat lowering blood pressure; don't eat anti pregnancy drugs, exclusion criteria: Changes in diet or physical activity every day; taking less than 80% of supplements given to patients at baseline(the compliance lower than %80); consumption of contraceptives, multivitamins and antioxidant supplements; renal , hepatic , thyroid, parathyroid diseases, cancer, heart diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
NFkB Jene expression amount. Timepoint: Before and after study. Method of measurement: PCR.;PPAR? Jene expression amount. Timepoint: Before and after study. Method of measurement: PCR.;Foxp3 Jene expression amount. Timepoint: Before and after study. Method of measurement: PCR.;GATA3 Jene expression amount. Timepoint: Before and after study. Method of measurement: PCR.;T-bet Jene expression amount. Timepoint: Before and after study. Method of measurement: PCR.;ROR? Jene expression amount. Timepoint: Before and after the study. Method of measurement: PCR.	—

Measure

Time frame

NFkB Jene expression amount. Timepoint: Before and after study. Method of measurement: PCR.;PPAR? Jene expression amount. Timepoint: Before and after study. Method of measurement: PCR.;Foxp3 Jene expression amount. Timepoint: Before and after study. Method of measurement: PCR.;GATA3 Jene expression amount. Timepoint: Before and after study. Method of measurement: PCR.;T-bet Jene expression amount. Timepoint: Before and after study. Method of measurement: PCR.;ROR? Jene expression amount. Timepoint: Before and after the study. Method of measurement: PCR.

—

Secondary

Measure	Time frame
BMI. Timepoint: Before and after study. Method of measurement: Formula.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNaheed Aryaeian

Iran University of Medical Sciences

nah_arya2002@yahoo.comaryaeian.n@iums.ac.iraryaeian@razi.tums.ac.ir+98 21 8670 4755

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026